Phase 3 Readout~month

Phase 3 Topline: Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic

Indication
Solid Organ Transplant Complications; Lymphoproliferative Disorders; Allogeneic Hematopoietic Cell Transplant

Other upcoming events for ATRA

Patent ExpiryPatent/Exclusivity Expiry: EXBLIFEP

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic — ATRA Phase 3 Readout | BioSniper